Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJAOA101 in Treatment of Diminished Ovarian Reserve
NCT05459493Phase 1Unknown
- Sponsor
- Tongji Hospital
- Start
- Nov 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TJAOA101 in Diminished Ovarian Reserve (DOR), sponsored by Tongji Hospital. Primary endpoint: Recovery rate of ovarian function at 6 months. Status: unknown.
02
Drugs
TJAOA101
03
Conditions
Diminished Ovarian Reserve (DOR)
Beyond the preview
Go deeper on NCT05459493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05459493.